Glaxo and Vir Biotechnology stocks climbed in premarket trading_老虎社区_美港股上老虎

Glaxo and Vir Biotechnology stocks climbed in premarket trading

Tiger Newspress2021-12-02

Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.

GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.

Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.

Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.

“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”

The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

128

TrillionDM
·2021-12-03
Follow
回复
1
举报
Troytan
·2021-12-02
Racing for trophy vaccine for omicron.
回复
3
举报
Kel9670ong
·2021-12-02
Any antibody or vaccine is a hope now
回复
2
举报
RashidMuzaki
·2021-12-02
Well, its an antibody, not a vaccine. Effect is relatively short-lived. We dont even know if Omicron causes severe repiratory problems that warrants its use.
回复
6
举报
收起
- GriseldaBrown:
  omicron is very horrible, till now no vaccine manufacturer has any new vaccines to deal with it.
  2021-12-03
  回复
  举报
- PorterLamb:
  Omicron coronavirus variant, first discovered in South Africa, has now been detected in Britain, Germany, Italy, the Netherlands, Denmark, Belgium, Botswana, Israel, Australia and Hong Kong. Antibodies produced by vaccination can protect us to some extent. But it cannot be 100% protected.
  2021-12-02
  回复
  举报
- PageDickens:
  It seems that the current vaccine does not work well against Omicron. I hope scientists can find a cure as soon as possible.
  2021-12-02
  回复
  举报
MHh
·2021-12-02
Next, how do all the intravenous and oral treatments compare against omicron, delta andmore variants to come. Looks like this will be an on-going battle and it will be living with covid
回复
9
举报
wltan
·2021-12-02
Ok
回复
4
举报
收起
- wltan:
  Ok
  2021-12-02
  回复
  举报
vxf
·2021-12-02
Start invested
回复
6
举报
收起
- TeslaLegend:
  Nice
  2021-12-02
  回复
  举报
Betterjob
·2021-12-02
Good turn
回复
6
举报
收起
- iHuat:
  Yes
  2021-12-02
  回复
  举报
- Michaeltql:
  Agree
  2021-12-02
  回复
  举报
財神發
·2021-12-02
Won
回复
5
举报
Mingfa
·2021-12-02
Ok
回复
6
举报
收起
- Mingfa:
  ok
  2021-12-02
  回复
  举报
Syracuse
·2021-12-02
To the moon
回复
4
举报
BC1970
·2021-12-02
Hi
回复
4
举报
Ashish
·2021-12-02
Like. Pls
回复
6
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-12-03
  回复
  举报
waiwaiho
·2021-12-02
Pls like,thanks
回复
7
举报
收起
- waiwaiho:
  Done
  2021-12-03
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-12-03
  回复
  举报
- waiwaiho:
  Thanks all
  2021-12-02
  回复
  举报
Lelelok92
·2021-12-02
Comment and like pls
回复
6
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-12-03
  回复
  举报
- Ashish:
  done
  2021-12-02
  回复
  举报
JFK
·2021-12-02
Like
回复
7
举报
收起
- BC1970:
  Hu
  2021-12-02
  回复
  举报
- Lelelok92:
  Ok
  2021-12-02
  回复
  举报
koolgal
·2021-12-02
Welcome the new Megastars Glaxo and Vir! Save the world!
回复
15
举报
收起
- koolgal:
  US.
  2021-12-03
  回复
  举报
- JeremyKok:
  for GSK which to buy, UK or US?
  2021-12-03
  回复
  举报
- koolgal:
  Yes!
  2021-12-03
  回复
  举报
查看更多 2 条评论
weilhw
·2021-12-02
Ok
回复
3
举报
收起
- JFK:
  Like
  2021-12-02
  回复
  举报
auahau
·2021-12-02
wow
回复
3
举报
收起
- weilhw:
  Ok
  2021-12-02
  回复
  举报
Alkid
·2021-12-02
Wow
回复
4
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1133804924?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-02 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133804924","market":"us","top_or_hot":-1,"title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","media":"Tiger Newspress","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n2021-12-02 17:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":null,"article_id":"1133804924","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","pubTimestamp":1638436562,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"translate_title":"葛兰素史克和Vir生物技术股票在盘前交易中攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.9,"VIR":0.9},"content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":601896783,"gmtCreate":1638504906979,"gmtModify":1638504957988,"author":{"id":"4088055457160620","authorId":"4088055457160620","name":"TrillionDM","avatar":"https://static.tigerbbs.com/2776ee51111cd85a7a6701f67bed0796","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088055457160620","authorIdStr":"4088055457160620"},"htmlText":"Follow","listText":"Follow","text":"Follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601896783","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603447737,"gmtCreate":1638445943562,"gmtModify":1638445943662,"author":{"id":"3571482048865852","authorId":"3571482048865852","name":"Troytan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3571482048865852","authorIdStr":"3571482048865852"},"htmlText":"Racing for trophy vaccine for omicron.&nbsp;","listText":"Racing for trophy vaccine for omicron.&nbsp;","text":"Racing for trophy vaccine for omicron.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603447737","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603422886,"gmtCreate":1638442749750,"gmtModify":1638442750921,"author":{"id":"3578468158955348","authorId":"3578468158955348","name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578468158955348","authorIdStr":"3578468158955348"},"htmlText":"Any antibody or vaccine is a hope now","listText":"Any antibody or vaccine is a hope now","text":"Any antibody or vaccine is a hope now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603422886","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603481892,"gmtCreate":1638439214953,"gmtModify":1638439881175,"author":{"id":"4099715187888740","authorId":"4099715187888740","name":"RashidMuzaki","avatar":"https://static.tigerbbs.com/026daf0ba0c501bd9d788378a4f935fd","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4099715187888740","authorIdStr":"4099715187888740"},"htmlText":"Well, its an antibody, not a vaccine. Effect is relatively short-lived. We dont even know if Omicron causes severe repiratory problems that warrants its use.","listText":"Well, its an antibody, not a vaccine. Effect is relatively short-lived. We dont even know if Omicron causes severe repiratory problems that warrants its use.","text":"Well, its an antibody, not a vaccine. Effect is relatively short-lived. We dont even know if Omicron causes severe repiratory problems that warrants its use.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/603481892","repostId":1133804924,"repostType":2,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6825701,"gmtCreate":1638499573000,"gmtModify":1638499573000,"authorId":9000000000000571,"author":{"id":9000000000000571,"idStr":"9000000000000571","authorId":9000000000000571,"name":"GriseldaBrown","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603481892,"type":1,"supId":0,"prevId":0,"content":"omicron is very horrible, till now no vaccine manufacturer has any new vaccines to deal with it.","text":"omicron is very horrible, till now no vaccine manufacturer has any new vaccines to deal with it.","html":"omicron is very horrible, till now no vaccine manufacturer has any new vaccines to deal with it."},{"id":6814063,"gmtCreate":1638442965801,"gmtModify":1638442965801,"authorId":9000000000000420,"author":{"id":9000000000000420,"idStr":"9000000000000420","authorId":9000000000000420,"name":"PorterLamb","avatar":"https://static.tigerbbs.com/9c61226b13dc84ab3139a9fa00b20782","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603481892,"type":1,"supId":0,"prevId":0,"content":"Omicron coronavirus variant, first discovered in South Africa, has now been detected in Britain, Germany, Italy, the Netherlands, Denmark, Belgium, Botswana, Israel, Australia and Hong Kong.\nAntibodies produced by vaccination can protect us to some extent. But it cannot be 100% protected.","text":"Omicron coronavirus variant, first discovered in South Africa, has now been detected in Britain, Germany, Italy, the Netherlands, Denmark, Belgium, Botswana, Israel, Australia and Hong Kong.\nAntibodies produced by vaccination can protect us to some extent. But it cannot be 100% protected.","html":"Omicron coronavirus variant, first discovered in South Africa, has now been detected in Britain, Germany, Italy, the Netherlands, Denmark, Belgium, Botswana, Israel, Australia and Hong Kong.\nAntibodies produced by vaccination can protect us to some extent. But it cannot be 100% protected."},{"id":6814048,"gmtCreate":1638442896809,"gmtModify":1638442896809,"authorId":9000000000000434,"author":{"id":9000000000000434,"idStr":"9000000000000434","authorId":9000000000000434,"name":"PageDickens","avatar":"https://static.tigerbbs.com/46c35ff83dd06ac0fd5a2fbfed0003e4","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603481892,"type":1,"supId":0,"prevId":0,"content":"It seems that the current vaccine does not work well against Omicron. I hope scientists can find a cure as soon as possible.","text":"It seems that the current vaccine does not work well against Omicron. I hope scientists can find a cure as soon as possible.","html":"It seems that the current vaccine does not work well against Omicron. I hope scientists can find a cure as soon as possible."}],"langContent":"CN"},{"id":603481096,"gmtCreate":1638439159439,"gmtModify":1638439880867,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"4091758936365950","authorIdStr":"4091758936365950"},"htmlText":"Next, how do all the intravenous and oral treatments compare against omicron, delta andmore variants to come. Looks like this will be an on-going battle and it will be living with covid&nbsp;","listText":"Next, how do all the intravenous and oral treatments compare against omicron, delta andmore variants to come. Looks like this will be an on-going battle and it will be living with covid&nbsp;","text":"Next, how do all the intravenous and oral treatments compare against omicron, delta andmore variants to come. Looks like this will be an on-going battle and it will be living with covid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603481096","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603418989,"gmtCreate":1638438163922,"gmtModify":1638438164357,"author":{"id":"3578894182511949","authorId":"3578894182511949","name":"wltan","avatar":"https://static.tigerbbs.com/578ac994ad69614ee393c7c08aca3a38","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578894182511949","authorIdStr":"3578894182511949"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603418989","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813317,"gmtCreate":1638438168276,"gmtModify":1638438168360,"authorId":3578894182511949,"author":{"id":3578894182511949,"idStr":"3578894182511949","authorId":3578894182511949,"name":"wltan","avatar":"https://static.tigerbbs.com/578ac994ad69614ee393c7c08aca3a38","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603418989,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":603435154,"gmtCreate":1638437594677,"gmtModify":1638437761074,"author":{"id":"3582839637303229","authorId":"3582839637303229","name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582839637303229","authorIdStr":"3582839637303229"},"htmlText":"Start invested","listText":"Start invested","text":"Start invested","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603435154","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813305,"gmtCreate":1638438111485,"gmtModify":1638438111515,"authorId":3572489627147183,"author":{"id":3572489627147183,"idStr":"3572489627147183","authorId":3572489627147183,"name":"TeslaLegend","avatar":"https://static.tigerbbs.com/180ad6f06095bcbf2b6594d26c494752","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603435154,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"CN"},{"id":603432786,"gmtCreate":1638437560229,"gmtModify":1638437750252,"author":{"id":"4087549167151930","authorId":"4087549167151930","name":"Betterjob","avatar":"https://static.tigerbbs.com/3a6e660c283e305dd2a1669316c2511b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087549167151930","authorIdStr":"4087549167151930"},"htmlText":"Good turn","listText":"Good turn","text":"Good turn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603432786","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813460,"gmtCreate":1638438958729,"gmtModify":1638438958830,"authorId":3577604413370961,"author":{"id":3577604413370961,"idStr":"3577604413370961","authorId":3577604413370961,"name":"iHuat","avatar":"https://static.tigerbbs.com/ba908ea2f329e3dce63ffec884debf23","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603432786,"type":1,"supId":0,"prevId":0,"content":"Yes ","text":"Yes ","html":"Yes "},{"id":6813238,"gmtCreate":1638437686718,"gmtModify":1638437686824,"authorId":3581511363085578,"author":{"id":3581511363085578,"idStr":"3581511363085578","authorId":3581511363085578,"name":"Michaeltql","avatar":"https://static.tigerbbs.com/5702cc9f095edfd93423e103aff18cfe","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603432786,"type":1,"supId":0,"prevId":0,"content":"Agree","text":"Agree","html":"Agree"}],"langContent":"CN"},{"id":603436251,"gmtCreate":1638437452199,"gmtModify":1638437738711,"author":{"id":"4088201880010570","authorId":"4088201880010570","name":"財神發","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4088201880010570","authorIdStr":"4088201880010570"},"htmlText":"Won","listText":"Won","text":"Won","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603436251","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603436973,"gmtCreate":1638437425216,"gmtModify":1638437735623,"author":{"id":"3577534578357163","authorId":"3577534578357163","name":"Mingfa","avatar":"https://static.tigerbbs.com/340b8324f26ec1c3e73989bb35cae23b","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3577534578357163","authorIdStr":"3577534578357163"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603436973","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813204,"gmtCreate":1638437442574,"gmtModify":1638437442599,"authorId":3577534578357163,"author":{"id":3577534578357163,"idStr":"3577534578357163","authorId":3577534578357163,"name":"Mingfa","avatar":"https://static.tigerbbs.com/340b8324f26ec1c3e73989bb35cae23b","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603436973,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":603431767,"gmtCreate":1638437370596,"gmtModify":1638437730928,"author":{"id":"3570889929256934","authorId":"3570889929256934","name":"Syracuse","avatar":"https://static.tigerbbs.com/decb32057fdbb92949b236b3b432eef4","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570889929256934","authorIdStr":"3570889929256934"},"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603431767","repostId":1133804924,"repostType":2,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603431587,"gmtCreate":1638437365540,"gmtModify":1638437730334,"author":{"id":"3554847287681495","authorId":"3554847287681495","name":"BC1970","avatar":"https://static.tigerbbs.com/0ddbf1d90da79b3d2d9ce69edd1f06d5","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3554847287681495","authorIdStr":"3554847287681495"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603431587","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603433054,"gmtCreate":1638437233153,"gmtModify":1638437719781,"author":{"id":"3554959936968759","authorId":"3554959936968759","name":"Ashish","avatar":"https://static.tigerbbs.com/3be2c16a3f991c655e70424d200c7389","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554959936968759","authorIdStr":"3554959936968759"},"htmlText":"Like. Pls","listText":"Like. Pls","text":"Like. Pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603433054","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6821307,"gmtCreate":1638486782393,"gmtModify":1638486782485,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603433054,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":603439292,"gmtCreate":1638437191141,"gmtModify":1638437717537,"author":{"id":"3573877891823690","authorId":"3573877891823690","name":"waiwaiho","avatar":"https://static.tigerbbs.com/b112a07bf435c07a2caef2264c1f3d2b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573877891823690","authorIdStr":"3573877891823690"},"htmlText":"Pls like,thanks&nbsp;","listText":"Pls like,thanks&nbsp;","text":"Pls like,thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/603439292","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6829960,"gmtCreate":1638527583084,"gmtModify":1638527583175,"authorId":3573877891823690,"author":{"id":3573877891823690,"idStr":"3573877891823690","authorId":3573877891823690,"name":"waiwaiho","avatar":"https://static.tigerbbs.com/b112a07bf435c07a2caef2264c1f3d2b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603439292,"type":1,"supId":6821309,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"},{"id":6821309,"gmtCreate":1638486793580,"gmtModify":1638486793672,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603439292,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6813185,"gmtCreate":1638437346661,"gmtModify":1638437346691,"authorId":3573877891823690,"author":{"id":3573877891823690,"idStr":"3573877891823690","authorId":3573877891823690,"name":"waiwaiho","avatar":"https://static.tigerbbs.com/b112a07bf435c07a2caef2264c1f3d2b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603439292,"type":1,"supId":0,"prevId":0,"content":"Thanks <u>all</u>","text":"Thanks <u>all</u>","html":"Thanks <u>all</u>"}],"langContent":"CN"},{"id":603430784,"gmtCreate":1638437131653,"gmtModify":1638437711876,"author":{"id":"3578056830476800","authorId":"3578056830476800","name":"Lelelok92","avatar":"https://static.tigerbbs.com/4e4265424827068345fa1eb8e5acd58b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578056830476800","authorIdStr":"3578056830476800"},"htmlText":"Comment and like pls","listText":"Comment and like pls","text":"Comment and like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603430784","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6821313,"gmtCreate":1638486800410,"gmtModify":1638486800444,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603430784,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6813163,"gmtCreate":1638437238640,"gmtModify":1638437238671,"authorId":3554959936968759,"author":{"id":3554959936968759,"idStr":"3554959936968759","authorId":3554959936968759,"name":"Ashish","avatar":"https://static.tigerbbs.com/3be2c16a3f991c655e70424d200c7389","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603430784,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":603430845,"gmtCreate":1638437085445,"gmtModify":1638437705478,"author":{"id":"3567221235003553","authorId":"3567221235003553","name":"JFK","avatar":"https://static.tigerbbs.com/d8cdaf8b81ae245f2f2ea5ff303a6722","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3567221235003553","authorIdStr":"3567221235003553"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603430845","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813192,"gmtCreate":1638437376278,"gmtModify":1638437376311,"authorId":3554847287681495,"author":{"id":3554847287681495,"idStr":"3554847287681495","authorId":3554847287681495,"name":"BC1970","avatar":"https://static.tigerbbs.com/0ddbf1d90da79b3d2d9ce69edd1f06d5","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603430845,"type":1,"supId":0,"prevId":0,"content":"Hu","text":"Hu","html":"Hu"},{"id":6813142,"gmtCreate":1638437139909,"gmtModify":1638437140007,"authorId":3578056830476800,"author":{"id":3578056830476800,"idStr":"3578056830476800","authorId":3578056830476800,"name":"Lelelok92","avatar":"https://static.tigerbbs.com/4e4265424827068345fa1eb8e5acd58b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603430845,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":603497806,"gmtCreate":1638437005807,"gmtModify":1638437005807,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Welcome the new Megastars Glaxo and Vir! Save the world!&nbsp;","listText":"Welcome the new Megastars Glaxo and Vir! Save the world!&nbsp;","text":"Welcome the new Megastars Glaxo and Vir! Save the world!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":15,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/603497806","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6821836,"gmtCreate":1638488209652,"gmtModify":1638488209652,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603497806,"type":1,"supId":6821334,"prevId":0,"content":"US.","text":"US.","html":"US."},{"id":6821334,"gmtCreate":1638486848450,"gmtModify":1638486848542,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603497806,"type":1,"supId":0,"prevId":0,"content":"for GSK which to buy, UK or US?","text":"for GSK which to buy, UK or US?","html":"for GSK which to buy, UK or US?"},{"id":6821264,"gmtCreate":1638486656823,"gmtModify":1638486656823,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603497806,"type":1,"supId":6820643,"prevId":0,"content":"Yes!","text":"Yes!","html":"Yes!"},{"id":6820643,"gmtCreate":1638483975656,"gmtModify":1638483975757,"authorId":4094345516143680,"author":{"id":4094345516143680,"idStr":"4094345516143680","authorId":4094345516143680,"name":"3f585b4d","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603497806,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":6813314,"gmtCreate":1638438152874,"gmtModify":1638438152874,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603497806,"type":1,"supId":6813296,"prevId":0,"content":"Yes! We badly need a solution to Omicron.","text":"Yes! We badly need a solution to Omicron.","html":"Yes! We badly need a solution to Omicron."}],"langContent":"CN"},{"id":603492383,"gmtCreate":1638436775897,"gmtModify":1638436776129,"author":{"id":"3575418941864095","authorId":"3575418941864095","name":"weilhw","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575418941864095","authorIdStr":"3575418941864095"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603492383","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813132,"gmtCreate":1638437073921,"gmtModify":1638437073952,"authorId":3567221235003553,"author":{"id":3567221235003553,"idStr":"3567221235003553","authorId":3567221235003553,"name":"JFK","avatar":"https://static.tigerbbs.com/d8cdaf8b81ae245f2f2ea5ff303a6722","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603492383,"type":1,"supId":0,"prevId":0,"content":"<u>Like</u>","text":"<u>Like</u>","html":"<u>Like</u>"}],"langContent":"CN"},{"id":603498780,"gmtCreate":1638436681836,"gmtModify":1638436682145,"author":{"id":"3575098313311401","authorId":"3575098313311401","name":"auahau","avatar":"https://static.tigerbbs.com/51a7e0e9a14e5faa1ff39d0755eb5e92","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575098313311401","authorIdStr":"3575098313311401"},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603498780","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6813085,"gmtCreate":1638436771923,"gmtModify":1638436772017,"authorId":3575418941864095,"author":{"id":3575418941864095,"idStr":"3575418941864095","authorId":3575418941864095,"name":"weilhw","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603498780,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":603498621,"gmtCreate":1638436649496,"gmtModify":1638436650050,"author":{"id":"3574044380631135","authorId":"3574044380631135","name":"Alkid","avatar":"https://static.tigerbbs.com/d584ca72b32575d58fab92034b2973bc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574044380631135","authorIdStr":"3574044380631135"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603498621","repostId":1133804924,"repostType":4,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohu8.com/m/news/1133804924?lang=&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p>\n<p><img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p>\n<p>Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p>\n<p>Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p>\n<p>“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p>\n<p>The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":128,"commentSize":21,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}